Candel Price Earnings Ratio from 2010 to 2024

CADL Stock  USD 5.05  0.09  1.75%   
Candel Therapeutics Price Earnings Ratio yearly trend continues to be quite stable with very little volatility. The value of Price Earnings Ratio is projected to decrease to -1.18. From the period between 2010 and 2024, Candel Therapeutics, Price Earnings Ratio regression line of its data series had sample variance of  93.82 and sample variance of  93.82. View All Fundamentals
 
Price Earnings Ratio  
First Reported
2010-12-31
Previous Quarter
(1.12)
Current Value
(1.18)
Quarterly Volatility
9.68610175
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Candel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Candel Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.2 M, Depreciation And Amortization of 596.5 K or Interest Expense of 358.1 K, as well as many indicators such as Price To Sales Ratio of 451, Dividend Yield of 0.0 or PTB Ratio of 3.5. Candel financial statements analysis is a perfect complement when working with Candel Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Candel Therapeutics Correlation against competitors.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

Latest Candel Therapeutics' Price Earnings Ratio Growth Pattern

Below is the plot of the Price Earnings Ratio of Candel Therapeutics over the last few years. It is Candel Therapeutics' Price Earnings Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Candel Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price Earnings Ratio10 Years Trend
Slightly volatile
   Price Earnings Ratio   
       Timeline  

Candel Price Earnings Ratio Regression Statistics

Arithmetic Mean(19.35)
Coefficient Of Variation(50.05)
Mean Deviation8.14
Median(25.46)
Standard Deviation9.69
Sample Variance93.82
Range24.3392
R-Value0.79
Mean Square Error37.98
R-Squared0.62
Significance0.0005
Slope1.71
Total Sum of Squares1,313

Candel Price Earnings Ratio History

2024 -1.18
2023 -1.12
2022 -18.0
2021 -6.2
2020 -9.2

About Candel Therapeutics Financial Statements

Candel Therapeutics investors utilize fundamental indicators, such as Price Earnings Ratio, to predict how Candel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Price Earnings Ratio(1.12)(1.18)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out the analysis of Candel Therapeutics Correlation against competitors.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Revenue Per Share
0.001
Return On Assets
(0.52)
Return On Equity
(4.81)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.